Promoter Hypermethylation of Tumor Suppressor Genes Located on Short Arm of the Chromosome 3 as Potential Biomarker for the Diagnosis of Nasopharyngeal Carcinoma

Lao, Thuan Duc; Nguyen, Thu Thi Hoai; Le, Thuy Ai Huyen

doi:10.3390/diagnostics11081404

Cited by 6 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The position of FAM107A on chromosome 3p14.3-p14.2 is characteristic, as several reports have indicated that genes in the short-arm area of chromosome 3, for the most part, have been identified and confirmed as TSGs. These genes are normally expressed in normal tissues but are inactivated in cancerous tissues [ 14 , 15 , 16 ]. The expression of FAM107A in normal tissues matched the above characteristics.…”

Section: Discussionmentioning

confidence: 99%

FAM107A Inactivation Associated with Promoter Methylation Affects Prostate Cancer Progression through the FAK/PI3K/AKT Pathway

Liu

Wang

et al. 2022

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is one of the most common cancers and is the second leading cause of mortality in men. Studies exploring novel therapeutic methods are urgently needed. FAM107A, a coding gene located in the short arm of chromosome3, is generally downregulated in PCa and is associated with a poor prognosis. However, the downregulation of FAM107A in PCa and the mechanism of its action remain challenging to determine. This investigation found that downregulation of FAM107A expression in PCa was caused by hypermethylation of CpG islands. Furthermore, DNA methyltransferase 1 (DNMT1) was involved in maintaining hypermethylation. Mechanistically, overexpression of FAM107A inhibits tumor cell proliferation, migration, invasion and promotes apoptosis through the FAK/PI3K/AKT signaling pathway, indicating that FAM107A may be a molecular brake of FAK/PI3K/AKT signaling, thus limiting the active state of the FAK/PI3K/AKT pathway. These findings will contribute to a better understanding of the effect of FAM107A in PCa, and FAM107A may represent a new therapeutic target for PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

FAM107A Inactivation Associated with Promoter Methylation Affects Prostate Cancer Progression through the FAK/PI3K/AKT Pathway

Liu

Wang

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…At the same time, based on logistic regression analysis, combined detection of IL-6 promoter methylation level and AFP can improve the diagnostic ability of AFP for HBV-associated HCC. Hypermethylation of genes in animals will silence genes, resulting in lower gene expression (30)(31)(32), while hypomethylation will reduce gene silencing and increase gene expression (33,34). So we guessed that the hypomethylation of IL-6 increased the expression of IL-6.…”

Section: Discussionmentioning

confidence: 99%

“…Hypermethylation of genes in animals will silence genes, resulting in lower gene expression ( 30 – 32 ), while hypomethylation will reduce gene silencing and increase gene expression ( 33 , 34 ). So we guessed that the hypomethylation of IL-6 increased the expression of IL-6.…”

Section: Discussionmentioning

confidence: 99%

IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma

Yang

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundNew biomarkers are needed to detect hepatocellular carcinoma at an earlier stage and to individualize treatment strategies. IL-6 has been proven to be associated with liver cancer in numerous studies.AimTo evaluate the value of the IL-6 promoter methylation level as a noninvasive biomarker for the diagnosis of liver cancer.MethodsA retrospective analysis of 165 patients with HBV-associated hepatocellular carcinoma (HCC), 198 patients with chronic hepatitis B (CHB) and 31 healthy controls were involved. The methylight was detected the methylation level of the IL-6 promoter in peripheral blood mononuclear cells (PBMCs), clinical and laboratory parameters were obtained.ResultsIL-6 promoter methylation levels were significantly lower in patients with HCC (median 53.59%, interquartile range 52.01–54.75%) than in those with CHB (median 56.05%, interquartile range 54.65–57.67%; P<0.001). The level of IL-6 mRNA in patients with HCC (median 0.371, interquartile range 0.173-0.671) was significantly higher than that in patients with CHB (median 0.203, interquartile range 0.108-0.354; P<0.001) and HCs (median 0.189, interquartile range 0.140-0.262; P=0.001). Meanwhile, the PMR value of IL-6 was notably negatively correlated with the mRNA expression level (Spearman’s R=-0.201, P<0.001). The IL-6 PMR value of HCC patients in age (Spearman’s R=0.193, P=0.026) and TBIL (Spearman’s R=0.186, P=0.032) were very weak correlated. At the same time, the level of IL-6 promoter methylation was also an independent factor in the development of liver cancer. When the IL-6 promoter methylation level was used to diagnose HCC, its detective value was superior to AFP [area under the receiver operating characteristic curve (AUC) 0.773 vs. 0.686, P=0.027], And the combined use of AFP and IL-6 methylation level can improve the area under the receiver operating characteristic curve (p=0.011).ConclusionIL-6 promoter hypomethylation is present in hepatocellular carcinoma, and it may be used as a noninvasive biomarker to detect early liver cancer.

show abstract

“…This suggests that there are important alternative mechanisms in the pathogenesis of NPC, such as epigenetic alterations, 7 such as the important epigenetic alteration of DNA methylation. At present, a large number of single gene‐based studies have reported the mechanism of gene silencing caused by hypermethylation of promoter regions of tumor suppressor genes in NPC, such as TP53, KRAS, ERBB2, and PIK3CA 51 . At the same time, as a populous country, China has the first new cases of NPC in the world every year and has a huge potential population susceptible to NPC.…”

Section: Cell‐free Dna and Dna Methylationmentioning

confidence: 99%

Early screening of nasopharyngeal carcinoma

Yue

et al. 2023

Head & Neck

View full text Add to dashboard Cite

The low positive predictive value (PPV) of early screening of nasopharyngeal carcinoma (NPC) is the problems that need to be solved urgently. The combination of cell‐free DNA (cfDNA) methylation testing and Epstein–Barr virus (EBV) serological testing is the key to solve this problem. This paper reviews recent advances in early screening for NPC and cfDNA methylation, with future perspectives. Pubmed was searched for the literature related to early screening of NPC and cfDNA methylation in the past 5 years. The results of these studies were summarized. Despite these efforts, the PPV is still low (10%). Previous studies have shown that cfDNA methylation analysis has good specificity and accuracy across a variety of tumors. The combination of cfDNA methylation and EBV detection helps to improve the PPV for early screening of NPC. The combination of cfDNA methylation and EBV serological testing is key to addressing the low PPV of NPC early screening.

show abstract

Promoter Hypermethylation of Tumor Suppressor Genes Located on Short Arm of the Chromosome 3 as Potential Biomarker for the Diagnosis of Nasopharyngeal Carcinoma

Cited by 6 publications

References 49 publications

FAM107A Inactivation Associated with Promoter Methylation Affects Prostate Cancer Progression through the FAK/PI3K/AKT Pathway

FAM107A Inactivation Associated with Promoter Methylation Affects Prostate Cancer Progression through the FAK/PI3K/AKT Pathway

IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma

Early screening of nasopharyngeal carcinoma

Contact Info

Product

Resources

About